Latest Fabry Stories

2010-10-29 05:55:00

CRANBURY, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will host a live conference call and webcast today, October 29, 2010 at 8:30 a.m.

2010-02-24 06:18:00

CAMBRIDGE, Massachusetts, February 24, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. Shire filed a BLA for REPLAGAL in December 2009.

2009-10-22 14:46:01

A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure.

2008-07-21 18:00:18

CyGene Laboratories Inc. (OTC:CYGE) ("the Company") announced today that it is introducing StrokeScan(TM), a genetic screening test aimed at identifying high risk individuals who have a family history of stroke, cardiovascular or kidney disease.

Word of the Day
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.